Search clinical trials for: Conjugate Vaccine

Total 10625 results

Public Health England

Completed

A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix

Vaccination

United Kingdom
Public Health England

Completed

A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years (DIPS)

Haemophilus Infections

United Kingdom
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Immunogenicity of PCV-7 Vaccine in VLBW Infants (PCV-7)

Pneumococcal Infections | Streptococcus Pneumoniae | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, Newborn

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Pneumococcal Infections
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
Korea University Guro Hospital

Completed

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

HIV/AIDS | Streptococcal Pneumonia
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
GlaxoSmithKline

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Infections, Meningococcal

Australia
GlaxoSmithKline

Completed

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Infections, Streptococcal

Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Celgene Corporation

Completed

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Multiple Myeloma

United States
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Infections, Streptococcal

Poland, Philippines
PATH
University of Maryland; Center for Vaccine Development - Mali

Completed

Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Diarrhea Rotavirus

Mali
Daiichi Sankyo, Inc.

Completed

Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a

Healthy

United Kingdom
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Pfizer

Completed

Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

Healthy Subjects

Japan
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Infections, Streptococcal

Spain, Greece
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Infections, Streptococcal

Mali
Johns Hopkins University

Completed

DNA Vaccine for Ragweed Allergic Adults

Seasonal Allergic Rhinitis

United States
Merck Sharp & Dohme LLC

Completed

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Pneumococcal Infections
Region Skane
Lund University

Completed

Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (PVA)

Rheumatoid Arthritis | Spondylarthropathy

Sweden
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Poland, Philippines
Pfizer
Kaiser Permanente

Completed

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Invasive Pneumococcal Disease

United States
LimmaTech Biologics AG

Completed

Phase I to Test a New Pneumococcal Vaccine

Pneumonia, Bacterial | Pneumococcal Pneumonia

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

Infections, Meningococcal

Thailand, Panama, Philippines
University of Texas Southwestern Medical Center

Withdrawn

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Lymphoma | Small Intestine Cancer | Brain and Central Nervous System Tumors | Lymphoproliferative Disorder

United States
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Pneumococcal Disease
Jiangsu Province Centers for Disease Control and...

Completed

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

Vaccine
University of Oxford

Completed

A Study of the Interaction Between BCG And MenC Immunisation: BAM (BAM)

Immune Response | BCG Infection | Reaction - Vaccine

United Kingdom
Menzies School of Health Research

Completed

Pneumococcal Vaccines Early and in Combination (PREVIX_COMBO)

Otitis Media

Australia
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Completed

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Dysentery, Bacillary | Dysentery

China
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
Novartis Vaccines

Completed

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Meningococcal Disease

Argentina
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Meningococcal Disease | Meningococcal Meningitis

United States, Canada
Novartis
Novartis Vaccines

Completed

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

Bacterial Meningitis

India
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Region Skane

Completed

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response (Vaccimil)

Syndrome | Vasculitis | SLE | Scleroderma | RA | Sjögrens

Sweden
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Pneumococcal Infection

United States
University of Campinas, Brazil

Completed

Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.

Generalized Aggressive Periodontitis

Brazil
GlaxoSmithKline

Completed

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Influenza

Spain, Poland, Philippines, Thailand, Belgium, United Kingdom, Czechia, Bangladesh, Dominican Republic, Honduras, Lebanon, Turkey, India
GlaxoSmithKline

Completed

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Infections, Meningococcal

Philippines, Lebanon
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Meningococcal Disease

Korea, Republic of

3

Subscribe